利用数据挖掘和网络药理学方法分析中药专利复方治疗肝纤维化的用药规律及机制.检索国家知识产权局中国专利公布公告网中治疗肝纤维化的中药专利复方,筛选整理后建立数据库,运用Microsoft Excel软件和中医传承计算平台(V3.0)对中药复方用药规律进行数据挖掘与分析.运用网络药理学方法探讨核心高频药对治疗肝纤维化的机制.最终筛选出专利复方147个,中药431味.高频药物包括黄芪、丹参、鳖甲和当归等,功效以补虚、活血化瘀和清热为主,核心高频药对黄芪-丹参治疗肝纤维化的主要活性成分为槲皮素、木犀草素、山奈酚和丹参酮ⅡA等,主要靶点为骨髓细胞瘤病毒癌基因(myelocytomatosis viral oncogene,MYC)、转录激活因子3(signal transducer and activator of transcription 3,STAT3)、丝氨酸/苏氨酸激酶1(serine/threonine kinase 1,AKT1)、雌激素受体1(estrogen receptor 1,ESR1)、FOS 原癌基因(FOS proto-oncogene,FOS)、缺氧诱导因子1亚基α(hypoxia-inducible factor 1 alpha,HIF-1a)、肿瘤蛋白p53(tumor protein p53,TP53)、丝裂原活化蛋白激酶14(mitogen-activated protein kinase 14,MAPK14)等,主要涉及磷脂酰肌醇3-激酶(phosphatidylinositol-3-kinase,PI3K)-蛋白激酶B(protein kinase B,Akt)、糖尿病并发症中晚期糖基化终产物及其受体(advanced glycation end products-recep-tor for advanced glycation end products,AGE-RAGE)、肿瘤坏死因子(tumor necrosis factor,TNF)、白细胞介素-17(interleukin-17,IL-17)、低氧诱导因子-1(hypoxia-inducible factor-1,HIF-1)、辅助性T细胞17(helper T cells 17,Th17)细胞分化信号等通路.结果表明:治疗肝纤维化的中药专利复方以补虚药、活血化瘀药和清热药为主,核心高频药对黄芪-丹参通过多成分、多靶点调控PI3K-Akt、AGE-RAGE、TNF和IL-17等通路来治疗肝纤维化.
Medication Regularity and Mechanism of Patented Chinese Herbal Compounds in Treating Hepatic Fibrosis
To analyze the medication regularity and mechanism of patented Chinese herbal compounds in treating hepatic fibrosis by using the methods of data mining and network pharmacology.The patent compounds of traditional Chinese medicine for the treatment of hepatic fibrosis in the China Patent Announcement Network of the State Intellectual Property Office was searched,and the database was established after screening and sorting.Microsoft Excel software and traditional Chinese medicine inheritance platform were used to conduct data mining and analysis on the medication rules of traditional Chinese medicine compound.To explore the mechanism of core high-frequency drug pairs in the treatment of hepatic fibrosis by network pharmacology.Finally,147 patent compounds were selected for the treatment of liver fibrosis,involving 431 kinds of traditional Chinese medicine.There are Huangqi,Danshen,Biejia,Danggui and other high frequency Chinese medicine.The main effect of these drugs is to replenish deficiency,promote blood stasis and clear heat.Huangqi-Danshen is core high-frequency drug pair that treat hepatic fibrosis through active ingredients such as quercetin,luteolin,kaempferol and tanshinone ⅡA.myelocytomatosis viral oncogene(MYC),signal transducer and activator of transcription 3(STAT3),serine/threonine kinase 1(AKT1),estrogen receptor 1(ESR1),FOS proto-oncogene(FOS),hypoxia-inducible factor 1 alpha(HIF1A),tumor protein p53(TP53)and mitogen-activated protein kinase14(MAPK14)are major therapeutic targets.It mainly involves phosphatidylinositol-3-kinase(PI3K)-protein kinase B(Akt),advanced glycation end products-receptor for advanced glycation end products(AGE-RAGE),tumor necrosis factor(TNF),interleukin-17(IL-17),hypoxia-inducible factor-1(HIF-1)and helper T cells 17(Th17)cell differentiation signaling pathways.The results show that the patented Chinese herbal compounds for the treatment of hepatic fibrosis are mainly tonic drugs,blood-activating and stasis-resolving drugs and heat-clearing drugs.Huangqi-Danshen is used to treat hepatic fibrosis by regulating PI3K-Akt,AGE-RAGE,TNF,IL-17 and other signaling pathways with multi-component and multi-target.
hepatic fibrosispatented Chinese herbal compoundsmedication rulesdata miningmechanism of actionnetwork pharmacology
万方数据
维普
